Koyfin Home > Directory > Health Care > Adma Biologics > Long-term Debt / Equity

Adma Biologics Long-term Debt / Equity Chart (ADMA)

Adma Biologics annual/quarterly Long-term Debt / Equity from 2010 to 2020.
  • Adma Biologics Long-term Debt / Equity for the quarter ending June 06, 2020 was $129m a -79.88% decrease of -103m year over year
  • Adma Biologics Long-term Debt / Equity for the last 12 months ending June 06, 2020 was $129m a -79.88% decrease of -103m year over year
  • Adma Biologics Annual Long-term Debt / Equity for 2019 was $323m a 35.04% increase of 113m from 2018
  • Adma Biologics Annual Long-term Debt / Equity for 2018 was $210m a 52.43% increase of 110m from 2017
  • Adma Biologics Annual Long-term Debt / Equity for 2017 was $100m a 377.28% increase of 376m from 2016
Other Ratios Metrics:
  • Adma Biologics Total Debt / Capital for the quarter ending September 09, 2018 was $53m a 4.96% increase of 3m year over year
  • Adma Biologics Other Liabilities for the quarter ending December 12, 2018 was $18m a -0.86% decrease of 0m year over year
  • Adma Biologics Total Debt / Equity for the quarter ending September 09, 2018 was $111m a 9.91% increase of 11m year over year
View Chart On Koyfin

Quarterly ADMA Long-term Debt / Equity Data

06/2020$129m
03/2020$102m
12/2019$323m
09/2019$233m
06/2019$179m
03/2019$570m
12/2018$210m
09/2018$111m
06/2018$79m
03/2018$176m

Annual ADMA Long-term Debt / Equity Data

2019$323m
2018$210m
2017$100m
2016$-276m
2015$1,740m
2014$243m
2013$23m
2012$41m
2011$23m
2010$-3m